Publications by authors named "Halyna Pylypenko"

Claim this Profile
E
Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Halyna Pylypenko

Hemasphere· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Halyna Pylypenko

Nat Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Halyna Pylypenko

Leukemia· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Halyna Pylypenko

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Sosana Delimpasi, Maria Victoria Mateos, Holger W Auner, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko

Am J Hematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Halyna Pylypenko

Am J Hematol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Halyna Pylypenko

Am J Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W Auner, Xavier Leleu, Halyna Pylypenko

J Hematol Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Halyna Pylypenko

Hemasphere· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Halyna Pylypenko

Lancet· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Halyna Pylypenko

Lancet Haematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
Tadeusz Robak, Huiqiang Huang, Jie Jin, Jun Zhu, Ting Liu, Halyna Pylypenko

Leuk Lymphoma· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Tadeusz Robak, Jie Jin, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul

Lancet Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP R-CHOP in the phase 3 LYM-3002 study.
Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, Halyna Pylypenko, Noppadol Siritanaratkul

Haematologica· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Thomas J Kipps, Herbert Eradat, Sebastian Grosicki, John Catalano, Walter Cosolo, Halyna Pylypenko

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Halyna Pylypenko

Lancet Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu

Haematologica· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Tadeusz Robak, Huiqiang Huang, Jie Jin, Jun Zhu, Ting Liu, Halyna Pylypenko

N Engl J Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu

Haematologica· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu

Lancet Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis